Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects. Ondansetron and later members of the 'setron class are currently standard treatments for cancer chemotherapy-related nausea and emesis. They are potent 5-HT3 blockers, but it is often not appreciated that mirtazapine and olanzapine bind with similar affinity to 5-HT3 receptors, have a longer half-life, are considerably cheaper than the 'setron class, and often offer better and smoother 24-h nausea control than 'setron class drugs. Mirtazapine and olanzapine often have salutary antianxiety effects and improve sleep quality. They occasionally relieve chemotherapy-related and advanced cancer-related nausea and appetite decrease better than the 'setron group that are specifically marketed for nausea control. Mirtazapine and olanzapine frequently give potent nausea reduction and appetite increase in advanced cancer-related cachexia. Several cytokine changes potentially induced by mirtazapine and olanzapine use are discussed that may have salutary effects in several cancers. We suggest mirtazapine and olanzapine be included as first-line options in treating both chemotherapy- and advanced cancer-related nausea. Multiple clinical and economic advantages of mirtazapine and olanzapine over currently used 'setron class medicines are reviewed. Double-blind studies against the 'setron class drugs are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Involvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer
Atreya, R., & Neurath, M. F. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:187 · Cited by 324
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275
Interleukin-6 regulation of prostate cancer cell growth.
Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20477 · Cited by 269
Passik, S. D., Lundberg, J., Kirsh, K. L., Theobald, D., Donaghy, K., Holtsclaw, E., Cooper, M., & Dugan, W. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00391-3 · Cited by 154
Passik, S. D., Kirsh, K. L., Theobald, D. E., Dickerson, P., Trowbridge, R., Gray, D., Beaver, M., Comparet, J., & Brown, J. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00078-2 · Cited by 56
Cited by
Depression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 375
Depression and end-of-life care for patients with cancer
Rosenstein, D. L. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/drosenstein · Cited by 92
Quimby, J. M., & Lunn, K. F. (2013) · The Veterinary Journal · doi:10.1016/j.tvjl.2013.05.048 · Cited by 90
Nausea and Vomiting: a Palliative Care Imperative
Wickham, R. J. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0871-6 · Cited by 40
Olanzapine for nausea and vomiting.
Licup, N., & Baumrucker, S. (2010) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909110369532 · Cited by 23
“Aside from having control on nausea, olanzapine has also noted to have other benefits in palliative care patients such as increased appetite and weight gain.(6,15) Other observations show that olanzapine can augment antidepressants in refractory melancholic depression.”
Background
Metadata
- Authors
- KAST, R. E., & FOLEY, K. F.
- Venue
- European Journal of Cancer Care
- Publisher
- Hindawi Limited
- Published
- 2007-07
- Volume
- 16
- Issue
- 4
- Pages
- 351-354
- ISSN
- 0961-5423 (ISSN-L)
- 1365-2354
- OpenAlex
- W1966630251
- Cited by
- 104
- References
- 5
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. https://app.cochat.ai/papers/10.1111/j.1365-2354.2006.00760.x
- The paper
- KAST, R. E., & FOLEY, K. F. (2007). Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. European Journal of Cancer Care. https://doi.org/10.1111/j.1365-2354.2006.00760.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.